Literature DB >> 2230000

Spontaneous reactivation in chronic hepatitis B: patterns and natural history.

S Gupta1, S Govindarajan, T L Fong, A G Redeker.   

Abstract

We identified spontaneous reactivation of hepatitis B virus (HBV) retrospectively by utilizing serum alanine aminotransferase and HBV DNA in 19 men (79% homosexual), with an estimated annual incidence of 7.3%. In 11 patients, spontaneous reactivation occurred as a single episode and in eight patients, reactivation was recurrent, with two to five episodes each. The mean serum alanine aminotransferase level was elevated over 10-fold at the peak of reactivation. Serum anti-HBc IgM was detected during 73% of the reactivation episodes. Actuarial analysis revealed that reactivation was long lasting with 45% and nearly 20% of episodes continued after 6 and 24 months, respectively. The course of 24 chronic HBV carriers with a negative serum HBV DNA test and normal alanine aminotransferase levels at initial appearance was unremarkable. We could not identify clinical features predictive of reactivation or its resolution. Severe reactivation hepatitis occurred in three patients (10%), with two deaths (6%). None of the patients lost HBsAg. Spontaneous reactivation in chronic hepatitis B can appear variably, persist long term, recur, and be fatal. Therefore, accurate classification of chronic HBV infection requires prolonged observation, and spontaneous reactivation should be considered a variable in therapeutic trials for chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230000     DOI: 10.1097/00004836-199010000-00015

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  29 in total

1.  Hepatobiliary quiz-9 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-03

Review 2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 3.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 4.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

5.  Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases.

Authors:  Han Hee Ryu; Eun Young Lee; Kichul Shin; In Ah Choi; Yun Jong Lee; Bin Yoo; Min-Chan Park; Yong-Beom Park; Sang-Cheol Bae; Wan Hee Yoo; Sung Il Kim; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2012-02-17       Impact factor: 2.980

6.  Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.

Authors:  Bilal Toka; Aydin Seref Koksal; Ahmet Tarik Eminler; Mukaddes Tozlu; Mustafa Ihsan Uslan; Erkan Parlak
Journal:  Dig Dis Sci       Date:  2020-07-29       Impact factor: 3.199

7.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

8.  Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B.

Authors:  T Laskus; J Rakela; M J Tong; D H Persing
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

Review 9.  Prevention and management of hepatitis B virus reactivation in cancer patients.

Authors:  Ka-Shing Cheung; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2016-01-06       Impact factor: 6.047

Review 10.  Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review.

Authors:  Byung Woog Kang; Soo Jung Lee; Joon Ho Moon; Shi-Nae Kim; Yee Soo Chae; Jong Gwang Kim; Yoon-Jin Hwang; Sang-Kyun Sohn
Journal:  Int J Hematol       Date:  2009-07-30       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.